ACC – Page 2 – Clinical Trial Results

Dr. Marianna Fontana and Dr. C. Michael Gibson Discuss: Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy

April 7, 2024

Disclosures: TBD

Dr. Gregg Stone and Dr. C. Michael Gibson Discuss: One-month Ticagrelor Monotherapy After Pci In Acute Coronary Syndromes: Principal Results From The Double-blind, Placebo-controlled Ultimate Dapt Trial

April 7, 2024

Disclosures: TBD

Dr. Gervasio Lamas and Dr. C. Michael Gibson Discuss: Effect Of Edetate Disodium Based Chelation Infusions On Cardiovascular Events In Post-MI Patients With Diabetes: The TACT2 Trial

April 7, 2024

Disclosures: TBD

Dr. Howard Herrmann and Dr. C. Michael Gibson Discuss: Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement In Patients With Small Aortic Annuli: Primary Outcomes From The Randomized Smart Trial

April 7, 2024

Disclosures: TBD

Dr. Daniel Gaudet and Dr. C. Michael Gibson Discuss: Plozasiran (ARO-APOC3), An Investigational RNAi Therapeutic, Demonstrates Profound And Durable Reductions In APOC-3 And Triglycerides (TG) In Patients With Severe Hypertriglyceridemia (SHTG), SHASTA-2 Final Results

April 7, 2024

Disclosures: TBD

Dr. Brian Bergmark and Dr. C. Michael Gibson Discuss: Efficacy And Safety Of Olezarsen In Patients With Hypertriglyceridemia And High Cardiovascular Risk: Primary Results Of The BRIDGE-TIMI 73a Trial

April 7, 2024

Disclosures: https://disclosures.acc.org/Public/AnnualMeetingAppConsol?pid=21006

Dr. Alexander Fanaroff and Dr. C. Michael Gibson Discuss: Effect Of Gamification, Financial Incentives Or Both Combined To Increase Physical Activity Among Patients With Elevated Risk For Major Adverse Cardiovascular Events. The Be Active Randomized Clinical Trial

April 7, 2024

Disclosures: TBD

Dr. C. Michael Gibson and Dr. Serge Korjian Discuss: CSL112 (Apolipoprotein A-I) Infusions And Cardiovascular Outcomes In Patients With Acute Myocardial Infarction (ApoA-I Event Reducing In Ischemic Syndromes II (AEGIS-II) Trial): Primary Trial Results

April 6, 2024

Disclosures: TBD

Dr. Javed Butler and Dr. C. Michael Gibson Discuss: Empagliflozin After Acute Myocardial Infarction: Results Of The EMPACT-MI Trial

April 6, 2024

Disclosures: TBD

Dr. Gregg Stone and Dr. C. Michael Gibson Discuss: A Double-blind, Randomized Placebo Procedure-controlled Trial Of An Interatrial Shunt In Patients With HfrEF And HfpEF: Principal Results From The RELIEVE-HF Trial

April 6, 2024

Disclosures: TBD